Clinical Trial Detail

NCT ID NCT02484053
Title Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Baylor College of Medicine
Indications

cancer

hematologic cancer

Therapies

Rituximab

Age Groups: child

No variant requirements are available.